Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.37 |
| ▸ | PPARD | Q03181 | 11/20 | 0.37 |
| ▸ | PPARA | Q07869 | 11/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401177 | 0.81 | MAPT (0.39) | ACHEPRMT5WDR77GRM4 | |
| SCHEMBL4402156 | 0.78 | ESR1 (0.44) | ACHE | |
| SCHEMBL2199302 | 0.76 | CA12 (0.46) | PPARGPPARDPPARAACHECA12 | |
| SCHEMBL2200446 | 0.74 | ESR1 (0.43) | — | |
| SCHEMBL2201085 | 0.70 | CA12 (0.49) | PPARGPPARDPPARACA12CA1 | |
| SCHEMBL9127265 | 0.66 | ESR2 (0.47) | — | |
| SCHEMBL6599554 | 0.65 | GHSR (0.34) | — | |
| SCHEMBL1940345 | 0.62 | ACHE (0.45) | ACHE | |
| SCHEMBL7094489 | 0.62 | LMNA (0.36) | CA12CA1CA9 | |
| SCHEMBL9700930 | 0.62 | PREP (0.40) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977364-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2011-07-12 | — | — | US | disclosed |
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERAMEX (FR) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | ESR1, ESR2, GPER1 | PPARG 75/4885PPARD 109/4885PPARA 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.